Mujoo K - Search Results

1

Adenoviral-mediated p53 tumor suppressor gene therapy of human ovarian carcinoma.

Mujoo K, Maneval DC, Anderson SC, Gutterman JU. Mujoo K, et al. Oncogene. 1996 Apr 18;12(8):1617-23. Oncogene. 1996. PMID: 8622881

2

Status of p53 phosphorylation and function in sensitive and resistant human cancer models exposed to platinum-based DNA damaging agents.

Mujoo K, Watanabe M, Nakamura J, Khokhar AR, Siddik ZH. Mujoo K, et al. J Cancer Res Clin Oncol. 2003 Dec;129(12):709-18. doi: 10.1007/s00432-003-0480-4. Epub 2003 Sep 26. J Cancer Res Clin Oncol. 2003. PMID: 14513366

3

Increased sensitivity of a metastatic model of prostate cancer to a novel tetravalent platinum analog.

Mujoo K, Watanabe M, Khokhar AR, Siddik ZH. Mujoo K, et al. Prostate. 2005 Jan 1;62(1):91-100. doi: 10.1002/pros.20114. Prostate. 2005. PMID: 15389812

4

Novel association of DJ-1 with HER3 potentiates HER3 activation and signaling in cancer.

Zhang S, Mukherjee S, Fan X, Salameh A, Mujoo K, Huang Z, Li L, To'a Salazar G, Zhang N, An Z. Zhang S, et al. Among authors: mujoo k. Oncotarget. 2016 Oct 4;7(40):65758-65769. doi: 10.18632/oncotarget.11613. Oncotarget. 2016. PMID: 27582551 Free PMC article.

5

Triterpenoid saponins from Acacia victoriae (Bentham) decrease tumor cell proliferation and induce apoptosis.

Mujoo K, Haridas V, Hoffmann JJ, Wächter GA, Hutter LK, Lu Y, Blake ME, Jayatilake GS, Bailey D, Mills GB, Gutterman JU. Mujoo K, et al. Cancer Res. 2001 Jul 15;61(14):5486-90. Cancer Res. 2001. PMID: 11454696

6

Emergence of cisplatin-resistant cells from the OVCAR-3 ovarian carcinoma cell line with p53 mutations, altered tumorigenicity, and increased apoptotic sensitivity to p53 gene replacement.

Mujoo K, Zhang L, Klostergaard J, Donato NJ. Mujoo K, et al. Int J Gynecol Cancer. 2000 Mar;10(2):105-114. doi: 10.1046/j.1525-1438.2000.00018.x. Int J Gynecol Cancer. 2000. PMID: 11240661

7

The E3 ubiquitin ligase NEDD4 negatively regulates HER3/ErbB3 level and signaling.

Huang Z, Choi BK, Mujoo K, Fan X, Fa M, Mukherjee S, Owiti N, Zhang N, An Z. Huang Z, et al. Among authors: mujoo k. Oncogene. 2015 Feb 26;34(9):1105-15. doi: 10.1038/onc.2014.56. Epub 2014 Mar 24. Oncogene. 2015. PMID: 24662824

8

Tumor necrosis factor alpha and gamma-interferon enhancement of anti-epidermal growth factor receptor monoclonal antibody binding to human melanoma cells.

Mujoo K, Donato NJ, Lapushin R, Rosenblum MG, Murray JL. Mujoo K, et al. J Immunother Emphasis Tumor Immunol. 1993 Apr;13(3):166-74. doi: 10.1097/00002371-199304000-00003. J Immunother Emphasis Tumor Immunol. 1993. PMID: 8471591

9

Pharmacokinetics, tissue distribution, and in vivo antitumor effects of the antimelanoma immunotoxin ZME-gelonin.

Mujoo K, Cheung L, Murray JL, Rosenblum MG. Mujoo K, et al. Cancer Immunol Immunother. 1995 May;40(5):339-45. doi: 10.1007/BF01519635. Cancer Immunol Immunother. 1995. PMID: 7600567

10

An antimelanoma immunotoxin containing recombinant human tumor necrosis factor: tissue disposition, pharmacokinetic, and therapeutic studies in xenograft models.

Rosenblum MG, Cheung L, Mujoo K, Murray JL. Rosenblum MG, et al. Among authors: mujoo k. Cancer Immunol Immunother. 1995 May;40(5):322-8. doi: 10.1007/BF01519633. Cancer Immunol Immunother. 1995. PMID: 7600565

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results